CNTX Stock Overview
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.
Context Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.92|
|52 Week High||US$10.87|
|52 Week Low||US$1.27|
|1 Month Change||-3.52%|
|3 Month Change||30.61%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-62.35%|
Recent News & Updates
Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Context Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|CNTX||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how CNTX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CNTX performed against the US Market.
|CNTX Average Weekly Movement||11.7%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CNTX's weekly volatility (12%) has been stable over the past year.
About the Company
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Context Therapeutics Fundamentals Summary
|CNTX fundamental statistics|
Is CNTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.81|
|Net Profit Margin||0.00%|
How did CNTX perform over the long term?See historical performance and comparison
Is CNTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNTX?
Other financial metrics that can be useful for relative valuation.
|What is CNTX's n/a Ratio?|
Price to Book Ratio vs Peers
How does CNTX's PB Ratio compare to its peers?
|CNTX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CPIX Cumberland Pharmaceuticals
ONTX Onconova Therapeutics
CNTX Context Therapeutics
Price-To-Book vs Peers: CNTX is expensive based on its Price-To-Book Ratio (0.7x) compared to the peer average (0.5x).
Price to Earnings Ratio vs Industry
How does CNTX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: CNTX is good value based on its Price-To-Book Ratio (0.7x) compared to the US Pharmaceuticals industry average (2x)
Price to Book Ratio vs Fair Ratio
What is CNTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.7x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate CNTX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CNTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CNTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CNTX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Context Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNTX is forecast to have no revenue next year.
High Growth Revenue: CNTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Context Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CNTX is currently unprofitable.
Growing Profit Margin: CNTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CNTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CNTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: CNTX has a negative Return on Equity (-28.64%), as it is currently unprofitable.
Discover strong past performing companies
How is Context Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CNTX's short term assets ($46.9M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: CNTX's short term assets ($46.9M) exceed its long term liabilities ($31.7K).
Debt to Equity History and Analysis
Debt Level: CNTX is debt free.
Reducing Debt: CNTX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CNTX has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 72.7% each year.
Discover healthy companies
What is Context Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CNTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CNTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Martin Lehr (38 yo)
Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. He was a...
CEO Compensation Analysis
Compensation vs Market: Martin's total compensation ($USD1.59M) is above average for companies of similar size in the US market ($USD767.72K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
Experienced Management: CNTX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: CNTX's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CNTX only recently listed within the past 12 months.
Context Therapeutics Inc.'s employee growth, exchange listings and data sources
- Name: Context Therapeutics Inc.
- Ticker: CNTX
- Exchange: NasdaqCM
- Founded: 2015
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$30.655m
- Shares outstanding: 15.97m
- Website: https://www.contexttherapeutics.com
Number of Employees
- Context Therapeutics Inc.
- 2001 Market Street
- Suite 3915
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.